Technical Analysis for CRY - CryoLife, Inc.

CRY closed up 1.96 percent on Friday, July 29, 2016, on 2.33 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, its overbought condition may remain that way and should be discounted.

Rating Last Price % Change $ Change
grade A $14.57 1.96% 0.28
Track This Stock
Watchlist Portfolio
ADX Long-Term Mid-Term Short-Term
Strong Up Up Up
See historical CRY trend table...

Date Name Bull/Bear % Chg
2016-07-29 New 52 Week High Bullish 0.00%
2016-07-28 New 52 Week High Bullish 1.96%
2016-07-28 Stochastic Reached Overbought Other 1.96%
2016-07-28 New Uptrend Bullish 1.96%
2016-07-28 Calm After Storm Range Contraction 1.96%
2016-07-27 New 52 Week High Bullish 3.70%
2016-07-27 Calm After Storm Range Contraction 3.70%
2016-07-26 New 52 Week High Bullish 5.96%
2016-07-26 Volume Surge Other 5.96%
2016-07-26 Wide Range Bar Range Expansion 5.96%

See older technical analysis pattern alerts for CRY ...
Buy or Sell?
Is CRY a Buy, Sell or Hold?:
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

Sector: Health Care

Industry: Medical/Dental Instruments

CryoLife, Inc. preserves and distributes human tissues for transplantation in the United States and internationally. The company also develops, manufactures, and commercializes medical devices for cardiac and vascular applications. It distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using CryoLifeÂ’s proprietary SynerGraft technology; and vascular tissues comprising CryoVein and CryoArtery to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company also distributes surgical sealants and hemostats, including BioGlue Surgical Adhesive, an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels, as well as in repair of cardiac, vascular, pulmonary, and additional soft tissues. In addition, its surgical sealants and hemostats comprise BioFoam Surgical Matrix for use as an adjunct in the sealing of abdominal parenchymal tissues, when cessation of bleeding by ligature or conventional methods is ineffective or impractical; PerClot, an absorbable powdered hemostat agent used in surgery; and revascularization technologies, which include transmyocardial revascularization system for treating patients with stable angina that is not responsive to conventional therapy. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization. The company, through its subsidiary, Hemosphere, Inc., markets HeRO Graft, a solution for end-stage renal disease in certain hemodialysis patients. CryoLife distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Recent Messages:
Earnings date: 2016-07-25

Indicator Value
52 Week High 14.73
52 Week Low 8.94
Average Volume 224,349
200-Day Moving Average 11.02
50-Day Moving Average 12.06
20-Day Moving Average 12.5
10-Day Moving Average 12.89
Average True Range 0.4
ADX 28.56
+DI 48.81
-DI: 8.41
Chandelier Exit (Long, 3 ATRs) 13.53
Chandelier Exit (Short, 3 ATRs) 12.77
Upper Bollinger Band 14.2
Lower Bollinger Band 10.8
Percent B (%b) 1.11
Bandwidth 0.272

You must be logged in to access portfolios.

Sign up